\-\ Texto\\:\\ \ \(0\)\
\-\ he\\ is\\ at\\ average\\ risk\\ for\\ colonic\\ polyps\\ and\\ colon\\ cancer\\.\\ he\\ states\\ he\\ is\\ doing\\ well\\ and\\ is\\ in\\ his\\ normal\\ state\\ of\\ health\\.\\ he\\ denies\\ change\\ in\\ bowel\\ movement\\,\\ weight\\ loss\\,\\ or\\ blood\\ in\\ his\\ stool\\.\\ he\\ has\\ no\\ history\\ of\\ rectal\\ bleeding\\,\\ hematochezia\\,\\ or\\ melena\\.\\ he\\ is\\ without\\ positive\\ stool\\ guaiac\\ test\\ or\\ history\\ of\\ iron\\ deficiency\\ anemia\\ within\\ the\\ past\\ 6\\ months\\.\\ the\\ patient\\ has\\ not\\ had\\ prior\\ evaluations\\ for\\ colon\\ cancer\\ screening\\.\\ his\\ past\\ medical\\ history\\ and\\ family\\ history\\ is\\ unremarkable\\ for\\ adenomatous\\ polyps\\,\\ colorectal\\ cancer\\,\\ inflammatory\\ bowel\\ disease\\,\\ hnpcc\\ or\\ faps\\.\ \(0\)\
\-\ polyp\\ was\\ biopsed\\ and\\ patient\\ received\\ appropriate\\ follow\\-up\\ care\\.\\ no\\ other\\ information\\ was\\ documented\ \(0\)\
\-\ a\\ still\\ image\\ from\\ the\\ 3\\-dimensional\\ endoluminal\\ fly\\-through\\ of\\ the\\ rectum\\ reveals\\ a\\ raised\\,\\ broad\\ based\\,\\ unilobular\\ lesion\\ with\\ smooth\\ contours\\ that\\ projects\\ into\\ the\\ lumen\\ of\\ the\\ rectum\\.\\ non\\-contrast\\ ct\\ cuts\\ in\\ the\\ cross\\-sectional\\ and\\ axial\\ views\\ from\\ the\\ same\\ level\\ of\\ the\\ endoluminal\\ still\\ image\\ confirms\\ the\\ presence\\ and\\ location\\ of\\ the\\ lesion\\.\\ the\\ lesion\\ is\\ a\\ well\\-demarcated\\ ovoid\\ mass\\ projecting\\ in\\ the\\ posterior\\ lumen\\ of\\ the\\ rectum\\ with\\ a\\ broad\\ base\\.\\ \\ attenuation\\ homogenous\\ to\\ surrounding\\ soft\\ tissue\\.\ \(0\)\
\-\ \\Â\\»\\ multimedia\\ links\\:\ \(0\)\
\-\ \\â\\€\\¢\\ http\\:\\/\\/rad\\.usuhs\\.mil\\/medpix\\/multimedia\\_files\\/ocvideo\\.mpg\ \(1\)\
\-\ \\â\\€\\¢\\ http\\:\\/\\/rad\\.usuhs\\.mil\\/medpix\\/multimedia\\_files\\/vcvideo\\.mpg\ \(1\)\
\-\ tubulovillous\\ adenoma\ \(1\)\
\-\ polyp\ \(200\)\
\-\ colon\\ cancer\ \(55\)\
\-\ lipoma\ \(291\)\
\-\ residual\\ fecal\\ matter\\ \\(untagged\\ feces\\)\ \(1\)\
\-\ foreign\\ body\ \(86\)\
\-\ lymphoma\ \(373\)\
\-\ this\\ 59\\ yo\\ man\\ presents\\ to\\ the\\ clinic\\ for\\ enrollment\\ in\\ the\\ virtual\\ colonoscopy\\ screening\\ protocol\\.\ \(0\)\
\-\ although\\ not\\ all\\ colon\\ polyps\\ will\\ develop\\ into\\ colon\\ cancer\\,\\ almost\\ all\\ sporadic\\ colon\\ cancer\\ arises\\ from\\ mucosal\\ colonic\\ polyps\\.\\ histology\\ of\\ the\\ polyps\\ is\\ a\\ critical\\ parameter\\ determining\\ malignant\\ potential\\ with\\ virtually\\ all\\ colon\\ cancers\\ believed\\ to\\ arise\\ from\\ adenomas\\.\\ killing\\ approximately\\ 60\\,000\\ americans\\ per\\ year\\,\\ colon\\ cancer\\ is\\ the\\ second\\ leading\\ cause\\ of\\ cancer\\-related\\ mortality\\ in\\ the\\ united\\ states\\.\\ \\ clinical\\ trials\\ have\\ shown\\ that\\ the\\ incidence\\ and\\ mortality\\ from\\ colon\\ cancer\\ can\\ decrease\\ with\\ early\\ detection\\ and\\ removal\\ of\\ premalignant\\ adenomatous\\ polyps\\.\\ appropriate\\ colon\\ cancer\\ screening\\,\\ therefore\\ is\\ important\\ to\\ prevent\\ colon\\ cancer\\ and\\ is\\ recommended\\ for\\ all\\ adults\\ over\\ 50\\ years\\ old\\.\\ \\ nonetheless\\,\\ despite\\ this\\ evidence\\,\\ less\\ than\\ one\\ fourth\\ of\\ the\\ eligible\\ population\\ in\\ the\\ united\\ states\\ participates\\ in\\ any\\ method\\ of\\ colon\\ cancer\\ screening\\.\ \(0\)\
\-\ currently\\ conventional\\ colonography\\ is\\ the\\ primary\\ screening\\ test\\ used\\ to\\ detect\\ colonic\\ polyps\\ and\\ cancers\\.\\ many\\ barriers\\ prevent\\ individuals\\ from\\ receiving\\ colonoscopy\\,\\ including\\ expense\\,\\ invasiveness\\,\\ patient\\ discomfort\\,\\ need\\ for\\ sedation\\ and\\ analgesia\\,\\ and\\ test\\ risks\\.\\ the\\ introduction\\ of\\ virtual\\ colonoscopy\\ \\(ct\\ colonography\\)\\ in\\ 1994\\ by\\ vining\\ was\\ to\\ maintain\\ the\\ desirable\\ features\\ of\\ colonoscopy\\ of\\ ease\\ of\\ lesion\\ detection\\ while\\ avoiding\\ the\\ undesirable\\ features\\ as\\ described\\ above\\.\\ since\\ 1994\\,\\ there\\ has\\ been\\ significant\\ progress\\ and\\ development\\ of\\ virtual\\ colonoscopy\\,\\ making\\ the\\ procedure\\ a\\ viable\\ alternative\\ in\\ screening\\ the\\ general\\ population\\ for\\ colon\\ cancer\\.\\ currently\\,\\ various\\ institutions\\ worldwide\\ perform\\ virtual\\ colonoscopy\\ on\\ an\\ elective\\ basis\\.\\ with\\ its\\ many\\ advantages\\,\\ this\\ technique\\ may\\ encourage\\ more\\ adults\\ to\\ seek\\ testing\\.\\ some\\ of\\ these\\ advantages\\ include\\:\\ lack\\ of\\ sedation\\,\\ minimal\\ invasiveness\\,\\ rare\\ test\\ complications\\,\\ detection\\ of\\ extracolonic\\ abnormalities\\,\\ and\\ convenience\\,\\ taking\\ 15\\ minutes\\ or\\ less\\.\\ however\\,\\ unlike\\ conventional\\ colonoscopy\\,\\ virtual\\ colonoscopy\\ is\\ not\\ therapeutic\\ and\\ requires\\ a\\ follow\\-up\\ procedure\\ with\\ conventional\\ colonoscopy\\ for\\ identified\\ polyps\\.\\ \ \(0\)\
\-\ virtual\\ colonoscopy\\ is\\ currently\\ under\\ intense\\ analysis\\ in\\ order\\ to\\ establish\\ the\\ procedure\\ as\\ a\\ primary\\ screening\\ method\\.\\ there\\ have\\ been\\ three\\ recent\\ multicenter\\ virtual\\ colonoscopy\\ clinical\\ trials\\ published\\,\\ which\\ report\\ widely\\ divergent\\ results\\ primarily\\ due\\ to\\ differences\\ in\\ ct\\ technology\\,\\ adjunctive\\ techniques\\,\\ ct\\ colonographic\\ interpretation\\,\\ and\\ study\\ design\\.\\ this\\ patient\\ was\\ in\\ a\\ prospective\\ multi\\-center\\ trial\\ published\\ in\\ 2003\\ by\\ pickhardt\\ et\\ al\\,\\ which\\ evaluated\\ the\\ use\\ of\\ virtual\\ colonoscopy\\ as\\ a\\ screening\\ tool\\ compared\\ with\\ traditional\\ colonoscopy\\.\\ in\\ this\\ study\\,\\ researchers\\ performed\\ both\\ conventional\\ and\\ virtual\\ colonoscopy\\ in\\ 1\\,233\\ asymptomatic\\ adults\\,\\ 97\\.4\\ percent\\ of\\ whom\\ were\\ at\\ average\\ risk\\ of\\ having\\ colonic\\ polyps\\.\\ pickhardt\\ and\\ associates\\ reported\\ a\\ sensitivity\\ of\\ 93\\.8\\%\\ for\\ polyps\\ at\\ least\\ 10\\ mm\\ in\\ diameter\\,\\ 93\\.9\\%\\ for\\ polyps\\ at\\ least\\ 8mm\\ in\\ diameter\\,\\ and\\ 88\\.7\\%\\ for\\ polyps\\ at\\ least\\ 6mm\\ in\\ diameter\\.\\ subsequently\\,\\ for\\ conventional\\ colonoscopy\\,\\ the\\ sensitivity\\ was\\ 87\\.5\\%\\,\\ 91\\.5\\%\\,\\ and\\ 92\\.3\\%\\ respectively\\ for\\ these\\ three\\ categories\\ of\\ polyp\\ size\\.\\ in\\ this\\ study\\,\\ virtual\\ colonoscopy\\ also\\ detected\\ two\\ malignant\\ polyps\\ while\\ conventional\\ colonoscopy\\ missed\\ one\\ of\\ them\\.\\ with\\ these\\ results\\,\\ pickhardt\\ et\\ al\\ demonstrated\\ that\\ virtual\\ colonoscopy\\ is\\ an\\ excellent\\ screening\\ test\\ for\\ colonic\\ polyps\\ and\\ rivals\\ conventional\\ colonoscopy\\.\\ furthermore\\,\\ a\\ metaanalysis\\ on\\ the\\ accuracy\\ of\\ virtual\\ colonoscopy\\ by\\ sosna\\ et\\ al\\ in\\ 2003\\ revealed\\ that\\ virtual\\ colonoscopy\\ is\\ an\\ accurate\\ tool\\ for\\ detecting\\ clinically\\ important\\ colorectal\\ polyps\\,\\ that\\ is\\,\\ polyps\\ that\\ are\\ greater\\ or\\ equal\\ to\\ 10\\ mm\\.\\ \\ the\\ future\\ of\\ virtual\\ colonoscopy\\ is\\ promising\\.\\ when\\ the\\ accuracy\\,\\ reliability\\,\\ and\\ cost\\-effectiveness\\ of\\ virtual\\ colonoscopy\\ is\\ established\\ in\\ detecting\\ polyps\\ and\\ cancers\\,\\ this\\ method\\ has\\ the\\ potential\\ to\\ improve\\ patient\\ participation\\ in\\ screening\\ programs\\ and\\ help\\ decrease\\ the\\ impact\\ of\\ colorectal\\ cancer\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ colonoscopy\\:\\ 0\\.47661452550049244\ \(0\)\
\-\ virtual\\:\\ 0\\.37526423768756567\ \(0\)\
\-\ polyps\\:\\ 0\\.364585403430162\ \(0\)\
\-\ colon\\:\\ 0\\.19683367387406053\ \(0\)\
\-\ cancer\\:\\ 0\\.18543093723768078\ \(0\)\
\-\ screening\\:\\ 0\\.16153688132978644\ \(0\)\
\-\ the\\:\\ 0\\.14284271517425534\ \(0\)\
\-\ conventional\\:\\ 0\\.14218245823458564\ \(0\)\
\-\ of\\:\\ 0\\.1206358865336878\ \(0\)\
\-\ in\\:\\ 0\\.11872407288297485\ \(0\)\
\-\ and\\:\\ 0\\.09861767153128767\ \(0\)\
\-\ is\\:\\ 0\\.09802341937974322\ \(0\)\
\-\ colonic\\:\\ 0\\.09703562671160423\ \(0\)\
\-\ pickhardt\\:\\ 0\\.0954031393896425\ \(0\)\
\-\ for\\:\\ 0\\.09040657613089591\ \(0\)\
\-\ test\\:\\ 0\\.08086663793166139\ \(0\)\
\-\ colorectal\\:\\ 0\\.07433132138114999\ \(0\)\
\-\ he\\:\\ 0\\.07065234712982883\ \(0\)\
\-\ method\\:\\ 0\\.06577344736152796\ \(0\)\
\-\ cancers\\:\\ 0\\.06407382744414329\ \(0\)\
\-\ invasiveness\\:\\ 0\\.06360209292642834\ \(0\)\
\-\ detection\\:\\ 0\\.06216711202180337\ \(0\)\
\-\ polyp\\:\\ 0\\.06074344429525646\ \(0\)\
\-\ rectum\\:\\ 0\\.060188022737956294\ \(0\)\
\-\ adults\\:\\ 0\\.05570998461641024\ \(0\)\
\-\ least\\:\\ 0\\.05513836796295909\ \(0\)\
\-\ endoluminal\\:\\ 0\\.05486784516999163\ \(0\)\
\-\ colonography\\:\\ 0\\.05486784516999163\ \(0\)\
\-\ advantages\\:\\ 0\\.05486784516999163\ \(0\)\
\-\ to\\:\\ 0\\.054684356360112756\ \(0\)\
\-\ states\\:\\ 0\\.05241169759885317\ \(0\)\
\-\ that\\:\\ 0\\.05177704663029163\ \(0\)\
\-\ published\\:\\ 0\\.05110996830450132\ \(0\)\
\-\ sedation\\:\\ 0\\.05055191154715929\ \(0\)\
\-\ tool\\:\\ 0\\.050035231691675425\ \(0\)\
\-\ trials\\:\\ 0\\.0495542142541\ \(0\)\
\-\ diameter\\:\\ 0\\.047945223777692496\ \(0\)\
\-\ this\\:\\ 0\\.04783081487443719\ \(0\)\
\-\ procedure\\:\\ 0\\.047560897754343925\ \(0\)\
\-\ al\\:\\ 0\\.04740041407442267\ \(0\)\
\-\ from\\:\\ 0\\.04738577152761719\ \(0\)\
\-\ all\\:\\ 0\\.047349164035131154\ \(0\)\
\-\ et\\:\\ 0\\.04673210931154632\ \(0\)\
\-\ accuracy\\:\\ 0\\.04657407992590502\ \(0\)\
\-\ adenomatous\\:\\ 0\\.045992744390677076\ \(0\)\
\-\ detecting\\:\\ 0\\.045992744390677076\ \(0\)\
\-\ currently\\:\\ 0\\.04582629677867971\ \(0\)\
\-\ 1994\\:\\ 0\\.04520261821335922\ \(0\)\
\-\ united\\:\\ 0\\.04345045716089051\ \(0\)\
\-\ or\\:\\ 0\\.041506610883377516\ \(0\)\
\-\ average\\:\\ 0\\.04144474134786891\ \(0\)\
\-\ sensitivity\\:\\ 0\\.04037000473504302\ \(0\)\
\-\ study\\:\\ 0\\.03978634021116312\ \(0\)\
\-\ stool\\:\\ 0\\.03966037706262832\ \(0\)\
\-\ mortality\\:\\ 0\\.03911964202227008\ \(0\)\
\-\ lesion\\:\\ 0\\.03813396788397944\ \(0\)\
\-\ population\\:\\ 0\\.037626604924020125\ \(0\)\
\-\ at\\:\\ 0\\.037554792681053335\ \(0\)\
\-\ prevent\\:\\ 0\\.036468370456922514\ \(0\)\
\-\ has\\:\\ 0\\.03633224273059306\ \(0\)\
\-\ his\\:\\ 0\\.03618000487143853\ \(0\)\
\-\ broad\\:\\ 0\\.035921267334983145\ \(0\)\
\-\ 2003\\:\\ 0\\.03579094601727969\ \(0\)\
\-\ potential\\:\\ 0\\.035537391256726815\ \(0\)\
\-\ lumen\\:\\ 0\\.035413990026439815\ \(0\)\
\-\ still\\:\\ 0\\.03523288925993766\ \(0\)\
\-\ appropriate\\:\\ 0\\.03494113173256878\ \(0\)\
\-\ was\\:\\ 0\\.03465125333830211\ \(0\)\
\-\ decrease\\:\\ 0\\.034183737951052895\ \(0\)\
\-\ important\\:\\ 0\\.03368906333477211\ \(0\)\
\-\ these\\:\\ 0\\.03368780729327396\ \(0\)\
\-\ patient\\:\\ 0\\.032338573921881685\ \(0\)\
\-\ features\\:\\ 0\\.032000865919017504\ \(0\)\
\-\ faps\\:\\ 0\\.03180104646321417\ \(0\)\
\-\ biopsed\\:\\ 0\\.03180104646321417\ \(0\)\
\-\ unilobular\\:\\ 0\\.03180104646321417\ \(0\)\
\-\ links\\:\\ 0\\.03180104646321417\ \(0\)\
\-\ untagged\\:\\ 0\\.03180104646321417\ \(0\)\
\-\ enrollment\\:\\ 0\\.03180104646321417\ \(0\)\
\-\ participates\\:\\ 0\\.03180104646321417\ \(0\)\
\-\ expense\\:\\ 0\\.03180104646321417\ \(0\)\
\-\ vining\\:\\ 0\\.03180104646321417\ \(0\)\
\-\ undesirable\\:\\ 0\\.03180104646321417\ \(0\)\
\-\ encourage\\:\\ 0\\.03180104646321417\ \(0\)\
\-\ extracolonic\\:\\ 0\\.03180104646321417\ \(0\)\
\-\ convenience\\:\\ 0\\.03180104646321417\ \(0\)\
\-\ colonographic\\:\\ 0\\.03180104646321417\ \(0\)\
\-\ rivals\\:\\ 0\\.03180104646321417\ \(0\)\
\-\ metaanalysis\\:\\ 0\\.03180104646321417\ \(0\)\
\-\ sosna\\:\\ 0\\.03180104646321417\ \(0\)\
\-\ many\\:\\ 0\\.03135684028575828\ \(0\)\
\-\ with\\:\\ 0\\.031150442954102124\ \(0\)\
\-\ results\\:\\ 0\\.03099068520722528\ \(0\)\
\-\ history\\:\\ 0\\.03038946037128968\ \(0\)\
\-\ hnpcc\\:\\ 0\\.030387597630566865\ \(0\)\
\-\ killing\\:\\ 0\\.030387597630566865\ \(0\)\
\-\ premalignant\\:\\ 0\\.030387597630566865\ \(0\)\
\-\ multicenter\\:\\ 0\\.030387597630566865\ \(0\)\
\-\ design\\:\\ 0\\.030387597630566865\ \(0\)\
\-\ associates\\:\\ 0\\.030387597630566865\ \(0\)\
\-\ ct\\:\\ 0\\.03028219849623365\ \(0\)\
\-\ http\\:\\ 0\\.029402578488562158\ \(0\)\
\-\ multimedia\\:\\ 0\\.029384739724056065\ \(0\)\
\-\ nonetheless\\:\\ 0\\.029384739724056065\ \(0\)\
\-\ barriers\\:\\ 0\\.029384739724056065\ \(0\)\
\-\ promising\\:\\ 0\\.029384739724056065\ \(0\)\
\-\ tubulovillous\\:\\ 0\\.028606862698855408\ \(0\)\
\-\ parameter\\:\\ 0\\.028606862698855408\ \(0\)\
\-\ ease\\:\\ 0\\.028606862698855408\ \(0\)\
\-\ mm\\:\\ 0\\.0284619226906997\ \(0\)\
\-\ risk\\:\\ 0\\.028416941970164544\ \(0\)\
\-\ malignant\\:\\ 0\\.02835001037612962\ \(0\)\
\-\ feces\\:\\ 0\\.027971290891408762\ \(0\)\
\-\ desirable\\:\\ 0\\.027971290891408762\ \(0\)\
\-\ divergent\\:\\ 0\\.027971290891408762\ \(0\)\
\-\ researchers\\:\\ 0\\.027971290891408762\ \(0\)\
\-\ programs\\:\\ 0\\.027971290891408762\ \(0\)\
\-\ participation\\:\\ 0\\.027433922584995815\ \(0\)\
\-\ less\\:\\ 0\\.027056698260842976\ \(0\)\
\-\ eligible\\:\\ 0\\.026968432984897966\ \(0\)\
\-\ introduction\\:\\ 0\\.026968432984897966\ \(0\)\
\-\ avoiding\\:\\ 0\\.026968432984897966\ \(0\)\
\-\ institutions\\:\\ 0\\.026968432984897966\ \(0\)\
\-\ technology\\:\\ 0\\.026968432984897966\ \(0\)\
\-\ adjunctive\\:\\ 0\\.026968432984897966\ \(0\)\
\-\ three\\:\\ 0\\.026697237856347734\ \(0\)\
\-\ americans\\:\\ 0\\.026557842058761456\ \(0\)\
\-\ worldwide\\:\\ 0\\.026557842058761456\ \(0\)\
\-\ analgesia\\:\\ 0\\.026190555959697305\ \(0\)\
\-\ whom\\:\\ 0\\.026190555959697305\ \(0\)\
\-\ past\\:\\ 0\\.025887744166912235\ \(0\)\
\-\ cuts\\:\\ 0\\.02585830526860235\ \(0\)\
\-\ differences\\:\\ 0\\.02585830526860235\ \(0\)\
\-\ reliability\\:\\ 0\\.02585830526860235\ \(0\)\
\-\ while\\:\\ 0\\.02570304495516906\ \(0\)\
\-\ evaluations\\:\\ 0\\.02555498415225066\ \(0\)\
\-\ bowel\\:\\ 0\\.025523112710835006\ \(0\)\
\-\ image\\:\\ 0\\.025434858526077717\ \(0\)\
\-\ by\\:\\ 0\\.025333452789087125\ \(0\)\
\-\ clinical\\:\\ 0\\.025204833951544034\ \(0\)\
\-\ traditional\\:\\ 0\\.025017615845837712\ \(0\)\
\-\ establish\\:\\ 0\\.024552126245739863\ \(0\)\
\-\ interpretation\\:\\ 0\\.024552126245739863\ \(0\)\
\-\ primary\\:\\ 0\\.02445472292366335\ \(0\)\
\-\ hematochezia\\:\\ 0\\.024340789193000756\ \(0\)\
\-\ guaiac\\:\\ 0\\.024340789193000756\ \(0\)\
\-\ 8mm\\:\\ 0\\.024340789193000756\ \(0\)\
\-\ melena\\:\\ 0\\.024141535319603353\ \(0\)\
\-\ fecal\\:\\ 0\\.024141535319603353\ \(0\)\
\-\ viable\\:\\ 0\\.024141535319603353\ \(0\)\
\-\ as\\:\\ 0\\.02396598472567905\ \(0\)\
\-\ contours\\:\\ 0\\.023953057324183416\ \(0\)\
\-\ projects\\:\\ 0\\.023604167013190406\ \(0\)\
\-\ alternative\\:\\ 0\\.023604167013190406\ \(0\)\
\-\ seek\\:\\ 0\\.023604167013190406\ \(0\)\
\-\ categories\\:\\ 0\\.023604167013190406\ \(0\)\
\-\ not\\:\\ 0\\.023550821137987375\ \(0\)\
\-\ elective\\:\\ 0\\.023441998529444247\ \(0\)\
\-\ 10\\:\\ 0\\.02325591672149327\ \(0\)\
\-\ been\\:\\ 0\\.023170891429927738\ \(0\)\
\-\ adenomas\\:\\ 0\\.023138677413092557\ \(0\)\
\-\ determining\\:\\ 0\\.022996372195338538\ \(0\)\
\-\ widely\\:\\ 0\\.022996372195338538\ \(0\)\
\-\ prospective\\:\\ 0\\.022996372195338538\ \(0\)\
\-\ an\\:\\ 0\\.02281230394417502\ \(0\)\
\-\ one\\:\\ 0\\.022770623302489905\ \(0\)\
\-\ accurate\\:\\ 0\\.02272808648695605\ \(0\)\
\-\ sporadic\\:\\ 0\\.02260130910667961\ \(0\)\
\-\ risks\\:\\ 0\\.02260130910667961\ \(0\)\
\-\ raised\\:\\ 0\\.022360800387891896\ \(0\)\
\-\ virtually\\:\\ 0\\.022246495270472264\ \(0\)\
\-\ missed\\:\\ 0\\.022246495270472264\ \(0\)\
\-\ unlike\\:\\ 0\\.02213581950658176\ \(0\)\
\-\ trial\\:\\ 0\\.02213581950658176\ \(0\)\
\-\ 6mm\\:\\ 0\\.02213581950658176\ \(0\)\
\-\ iron\\:\\ 0\\.021924482453842653\ \(0\)\
\-\ critical\\:\\ 0\\.021924482453842653\ \(0\)\
\-\ maintain\\:\\ 0\\.021629715927673186\ \(0\)\
\-\ them\\:\\ 0\\.021629715927673186\ \(0\)\
\-\ furthermore\\:\\ 0\\.021629715927673186\ \(0\)\
\-\ detect\\:\\ 0\\.021446200201774235\ \(0\)\
\-\ established\\:\\ 0\\.021446200201774235\ \(0\)\
\-\ documented\\:\\ 0\\.021271864188223598\ \(0\)\
\-\ projecting\\:\\ 0\\.021271864188223598\ \(0\)\
\-\ arises\\:\\ 0\\.021271864188223598\ \(0\)\
\-\ believed\\:\\ 0\\.021271864188223598\ \(0\)\
\-\ basis\\:\\ 0\\.021271864188223598\ \(0\)\
\-\ techniques\\:\\ 0\\.021187860274032303\ \(0\)\
\-\ into\\:\\ 0\\.021141447899734066\ \(0\)\
\-\ doing\\:\\ 0\\.021105833107129508\ \(0\)\
\-\ homogenous\\:\\ 0\\.021105833107129508\ \(0\)\
\-\ histology\\:\\ 0\\.021105833107129508\ \(0\)\
\-\ impact\\:\\ 0\\.021025691790286145\ \(0\)\
\-\ individuals\\:\\ 0\\.02079576272681113\ \(0\)\
\-\ receiving\\:\\ 0\\.02065049196761936\ \(0\)\
\-\ respectively\\:\\ 0\\.020580065456180435\ \(0\)\
\-\ perform\\:\\ 0\\.020511033621195347\ \(0\)\
\-\ technique\\:\\ 0\\.020511033621195347\ \(0\)\
\-\ excellent\\:\\ 0\\.02044334229526344\ \(0\)\
\-\ progress\\:\\ 0\\.020247814765085484\ \(0\)\
\-\ rectal\\:\\ 0\\.02012330175237801\ \(0\)\
\-\ therapeutic\\:\\ 0\\.02012330175237801\ \(0\)\
\-\ state\\:\\ 0\\.020062674245985433\ \(0\)\
\-\ future\\:\\ 0\\.019944493648733793\ \(0\)\
\-\ making\\:\\ 0\\.01988687260544249\ \(0\)\
\-\ various\\:\\ 0\\.01988687260544249\ \(0\)\
\-\ have\\:\\ 0\\.019867672849633203\ \(0\)\
\-\ ovoid\\:\\ 0\\.01983018853131416\ \(0\)\
\-\ health\\:\\ 0\\.019665465270062774\ \(0\)\
\-\ information\\:\\ 0\\.019665465270062774\ \(0\)\
\-\ percent\\:\\ 0\\.019665465270062774\ \(0\)\
\-\ deficiency\\:\\ 0\\.0194572843911471\ \(0\)\
\-\ protocol\\:\\ 0\\.019407125342320846\ \(0\)\
\-\ improve\\:\\ 0\\.01930892184128715\ \(0\)\
\-\ taking\\:\\ 0\\.01926083840654416\ \(0\)\
\-\ requires\\:\\ 0\\.01926083840654416\ \(0\)\
\-\ well\\:\\ 0\\.019257194886688235\ \(0\)\
\-\ confirms\\:\\ 0\\.019213409188515083\ \(0\)\
\-\ primarily\\:\\ 0\\.01907487465122589\ \(0\)\
\-\ detected\\:\\ 0\\.01907487465122589\ \(0\)\
\-\ equal\\:\\ 0\\.019029893462616135\ \(0\)\
\-\ 59\\:\\ 0\\.018855557449065495\ \(0\)\
\-\ minutes\\:\\ 0\\.018813302462010063\ \(0\)\
\-\ intense\\:\\ 0\\.0187715535348742\ \(0\)\
\-\ mucosal\\:\\ 0\\.018730298689483886\ \(0\)\
\-\ analysis\\:\\ 0\\.018492525156203185\ \(0\)\
\-\ discomfort\\:\\ 0\\.018379455987653028\ \(0\)\
\-\ order\\:\\ 0\\.018379455987653028\ \(0\)\
\-\ movement\\:\\ 0\\.018306063934776354\ \(0\)\
\-\ develop\\:\\ 0\\.018306063934776354\ \(0\)\
\-\ need\\:\\ 0\\.018306063934776354\ \(0\)\
\-\ anemia\\:\\ 0\\.018269939323939412\ \(0\)\
\-\ help\\:\\ 0\\.018269939323939412\ \(0\)\
\-\ arise\\:\\ 0\\.018198794124991532\ \(0\)\
\-\ which\\:\\ 0\\.01808415730594819\ \(0\)\
\-\ almost\\:\\ 0\\.017863343806549557\ \(0\)\
\-\ testing\\:\\ 0\\.017863343806549557\ \(0\)\
\-\ fourth\\:\\ 0\\.01783150802592738\ \(0\)\
\-\ leading\\:\\ 0\\.01767654945943564\ \(0\)\
\-\ therefore\\:\\ 0\\.01752818690957569\ \(0\)\
\-\ received\\:\\ 0\\.017303206028265558\ \(0\)\
\-\ despite\\:\\ 0\\.017303206028265558\ \(0\)\
\-\ having\\:\\ 0\\.01714351427197694\ \(0\)\
\-\ incidence\\:\\ 0\\.017117595983439184\ \(0\)\
\-\ lack\\:\\ 0\\.017015807912681053\ \(0\)\
\-\ evaluated\\:\\ 0\\.016990818603162743\ \(0\)\
\-\ subsequently\\:\\ 0\\.016966007155005725\ \(0\)\
\-\ clinic\\:\\ 0\\.016750309884375026\ \(0\)\
\-\ report\\:\\ 0\\.016750309884375026\ \(0\)\
\-\ clinically\\:\\ 0\\.016525329003064894\ \(0\)\
\-\ per\\:\\ 0\\.016503609345576046\ \(0\)\
\-\ under\\:\\ 0\\.01646057183906284\ \(0\)\
\-\ development\\:\\ 0\\.016439250709907392\ \(0\)\
\-\ smooth\\:\\ 0\\.016418059193280078\ \(0\)\
\-\ bleeding\\:\\ 0\\.0162530109127986\ \(0\)\
\-\ described\\:\\ 0\\.016134158705150916\ \(0\)\
\-\ compared\\:\\ 0\\.016076218417045082\ \(0\)\
\-\ denies\\:\\ 0\\.0160381197454782\ \(0\)\
\-\ general\\:\\ 0\\.01596314924849493\ \(0\)\
\-\ adenoma\\:\\ 0\\.01585363258478131\ \(0\)\
\-\ there\\:\\ 0\\.015824659380754173\ \(0\)\
\-\ recommended\\:\\ 0\\.015817878489303154\ \(0\)\
\-\ same\\:\\ 0\\.01573006543932963\ \(0\)\
\-\ views\\:\\ 0\\.01569555036776708\ \(0\)\
\-\ family\\:\\ 0\\.015644410177997153\ \(0\)\
\-\ shown\\:\\ 0\\.015415201286769278\ \(0\)\
\-\ complications\\:\\ 0\\.015230060767669232\ \(0\)\
\-\ attenuation\\:\\ 0\\.015215067223050362\ \(0\)\
\-\ use\\:\\ 0\\.015215067223050362\ \(0\)\
\-\ removal\\:\\ 0\\.015200137890810725\ \(0\)\
\-\ minimal\\:\\ 0\\.015170469679821483\ \(0\)\
\-\ matter\\:\\ 0\\.015141051836466194\ \(0\)\
\-\ reveals\\:\\ 0\\.015126435489057826\ \(0\)\
\-\ base\\:\\ 0\\.015126435489057826\ \(0\)\
\-\ change\\:\\ 0\\.015068575343345235\ \(0\)\
\-\ rare\\:\\ 0\\.015011659895390788\ \(0\)\
\-\ second\\:\\ 0\\.014886899289107457\ \(0\)\
\-\ used\\:\\ 0\\.014886899289107457\ \(0\)\
\-\ its\\:\\ 0\\.014714224300865726\ \(0\)\
\-\ greater\\:\\ 0\\.014650023706396228\ \(0\)\
\-\ based\\:\\ 0\\.014404429656655846\ \(0\)\
\-\ since\\:\\ 0\\.014404429656655846\ \(0\)\
\-\ abnormalities\\:\\ 0\\.014404429656655846\ \(0\)\
\-\ above\\:\\ 0\\.014345642534159877\ \(0\)\
\-\ early\\:\\ 0\\.014334003145216925\ \(0\)\
\-\ reported\\:\\ 0\\.014322402489753049\ \(0\)\
\-\ presence\\:\\ 0\\.014287830367551008\ \(0\)\
\-\ including\\:\\ 0\\.01423096134534985\ \(0\)\
\-\ care\\:\\ 0\\.014208470985082272\ \(0\)\
\-\ identified\\:\\ 0\\.014098145519513909\ \(0\)\
\-\ 50\\:\\ 0\\.013887447336702337\ \(0\)\
\-\ weight\\:\\ 0\\.013867061350242899\ \(0\)\
\-\ location\\:\\ 0\\.01384679388763023\ \(0\)\
\-\ cause\\:\\ 0\\.013546842509336826\ \(0\)\
\-\ although\\:\\ 0\\.013537583556350909\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.013537583556350909\ \(0\)\
\-\ recent\\:\\ 0\\.013464384147709025\ \(0\)\
\-\ size\\:\\ 0\\.013464384147709025\ \(0\)\
\-\ inflammatory\\:\\ 0\\.013446321963518689\ \(0\)\
\-\ 15\\:\\ 0\\.013437325845623209\ \(0\)\
\-\ unremarkable\\:\\ 0\\.01333114523870613\ \(0\)\
\-\ surrounding\\:\\ 0\\.01326211340372104\ \(0\)\
\-\ positive\\:\\ 0\\.013103441988066032\ \(0\)\
\-\ body\\:\\ 0\\.013087152268004311\ \(0\)\
\-\ revealed\\:\\ 0\\.01303873490982126\ \(0\)\
\-\ no\\:\\ 0\\.012932996489858779\ \(0\)\
\-\ any\\:\\ 0\\.01285152247758453\ \(0\)\
\-\ will\\:\\ 0\\.012798760483892259\ \(0\)\
\-\ approximately\\:\\ 0\\.012688318498880555\ \(0\)\
\-\ medical\\:\\ 0\\.012637952387968183\ \(0\)\
\-\ some\\:\\ 0\\.01251168529002448\ \(0\)\
\-\ yo\\:\\ 0\\.01242325534099319\ \(0\)\
\-\ demonstrated\\:\\ 0\\.012221017522410513\ \(0\)\
\-\ years\\:\\ 0\\.012189469852350908\ \(0\)\
\-\ loss\\:\\ 0\\.012114900297774182\ \(0\)\
\-\ level\\:\\ 0\\.012011918189069853\ \(0\)\
\-\ when\\:\\ 0\\.012011918189069853\ \(0\)\
\-\ on\\:\\ 0\\.012011450203813018\ \(0\)\
\-\ include\\:\\ 0\\.01183161811290132\ \(0\)\
\-\ two\\:\\ 0\\.011809018398416093\ \(0\)\
\-\ however\\:\\ 0\\.011769818055623205\ \(0\)\
\-\ performed\\:\\ 0\\.011764253818608086\ \(0\)\
\-\ months\\:\\ 0\\.011574898070760032\ \(0\)\
\-\ blood\\:\\ 0\\.01154866774572377\ \(0\)\
\-\ axial\\:\\ 0\\.011486508706562955\ \(0\)\
\-\ significant\\:\\ 0\\.01148137847200958\ \(0\)\
\-\ due\\:\\ 0\\.011430487148472128\ \(0\)\
\-\ evidence\\:\\ 0\\.011286969621977026\ \(0\)\
\-\ than\\:\\ 0\\.01127245470683646\ \(0\)\
\-\ prior\\:\\ 0\\.011125903219663285\ \(0\)\
\-\ both\\:\\ 0\\.011089062784320276\ \(0\)\
\-\ over\\:\\ 0\\.011057143717302048\ \(0\)\
\-\ more\\:\\ 0\\.010919198717439614\ \(0\)\
\-\ soft\\:\\ 0\\.010586551417464335\ \(0\)\
\-\ man\\:\\ 0\\.010527565344298015\ \(0\)\
\-\ without\\:\\ 0\\.010488788595749834\ \(0\)\
\-\ can\\:\\ 0\\.010435215738426427\ \(0\)\
\-\ tissue\\:\\ 0\\.010431420426402268\ \(0\)\
\-\ other\\:\\ 0\\.010326795397673096\ \(0\)\
\-\ posterior\\:\\ 0\\.010282899828177873\ \(0\)\
\-\ were\\:\\ 0\\.01025033711735812\ \(0\)\
\-\ may\\:\\ 0\\.010006948601835087\ \(0\)\
\-\ had\\:\\ 0\\.009907625822015135\ \(0\)\
\-\ presents\\:\\ 0\\.009565892653125303\ \(0\)\
\-\ also\\:\\ 0\\.009353511316465103\ \(0\)\
\-\ within\\:\\ 0\\.00915859133160193\ \(0\)\
\-\ disease\\:\\ 0\\.008347174721161636\ \(0\)\
\-\ normal\\:\\ 0\\.008119065985222768\ \(0\)\
\-\ mass\\:\\ 0\\.007595683069267542\ \(0\)\
\-\ are\\:\\ 0\\.00754559609052161\ \(0\)\
\-\ year\\:\\ 0\\.006128281601042698\ \(0\)\
\-\ old\\:\\ 0\\.005885271694322015\ \(0\)\
